Safety of long-acting beta2-agonists in the management of asthma: a Primary Care Respiratory Alliance of Canada perspective.
作者信息
D'Urzo Anthony D, Jugovic Pieter, Bouchard Jacques, Jhirad Reuven, Tamari Itamar
机构信息
Department of Family and Community Medicine, University of Toronto, Ontario, Canada.
出版信息
Can Fam Physician. 2010 Feb;56(2):119-20, 123-4.
Abstract
摘要
相似文献
1
Safety of long-acting beta2-agonists in the management of asthma: a Primary Care Respiratory Alliance of Canada perspective.长效β2受体激动剂在哮喘管理中的安全性：加拿大初级保健呼吸联盟的观点
Can Fam Physician. 2010 Feb;56(2):119-20, 123-4.
2
Canadian Thoracic Society Asthma Committee commentary on long-acting beta-2 agonist use for asthma in Canada.加拿大胸科学会哮喘委员会关于加拿大哮喘患者使用长效β2受体激动剂的评论。
Can Respir J. 2010 Mar-Apr;17(2):57-60. doi: 10.1155/2010/378289.
3
Assessment of the safety of long-acting β2-agonists in routine asthma care: the ASTRO-LAB protocol.长效β2受体激动剂在常规哮喘治疗中的安全性评估：ASTRO-LAB方案。
NPJ Prim Care Respir Med. 2015 Jun 18;25:15040. doi: 10.1038/npjpcrm.2015.40.
4
Long-acting β₂ agonists for asthma: a clinical paradox.用于哮喘的长效β₂激动剂：一个临床悖论。
Consult Pharm. 2010 Nov;25(11):756-9. doi: 10.4140/TCP.n.2010.756.
5
[Not Available].[无可用内容]
Praxis (Bern 1994). 2018;107(21):1169-1170. doi: 10.1024/1661-8157/a003073.
6
The safety of regular long-acting beta2-agonists in children with asthma: an overview of Cochrane reviews.
Paediatr Respir Rev. 2013 Mar;14(1):25-6. doi: 10.1016/j.prrv.2012.10.002. Epub 2012 Nov 21.
7
Long acting β2 agonists in adult asthma.长效β2受体激动剂在成人哮喘中的应用
BMJ. 2013 Aug 6;347:f4662. doi: 10.1136/bmj.f4662.
8
Cost effectiveness of leukotriene receptor antagonists versus long-acting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: a pragmatic trial.白三烯受体拮抗剂与长效β2 激动剂作为哮喘吸入皮质激素的附加治疗的成本效果：一项实用试验。
Pharmacoeconomics. 2010;28(7):597-608. doi: 10.2165/11537560-000000000-00000.
9
LABAs in asthmatic children: highlights and new inside.LABA 在哮喘儿童中的应用：要点和新进展。
Pulm Pharmacol Ther. 2013 Oct;26(5):540-3. doi: 10.1016/j.pupt.2013.04.002. Epub 2013 Apr 11.
10
The use of long-acting β2- agonists as monotherapy in children and adults.长效β2受体激动剂在儿童和成人中作为单一疗法的应用。
J Popul Ther Clin Pharmacol. 2013;20(1):e1-12. Epub 2013 Jan 23.
引用本文的文献
1
Cover concerns.涵盖相关问题。
Can Fam Physician. 2010 Apr;56(4):329-30.
本文引用的文献
1
Risks of long-acting beta-agonists in achieving asthma control.长效β受体激动剂在实现哮喘控制方面的风险。
N Engl J Med. 2009 Apr 16;360(16):1671-2. doi: 10.1056/NEJMe0902057.
2
Balancing the benefits and risks of inhaled long-acting beta-agonists--the influence of values.权衡吸入长效β受体激动剂的利弊——价值观的影响
N Engl J Med. 2009 Apr 16;360(16):1592-5. doi: 10.1056/NEJMp0810561.
3
The coming of age of asthma guidelines.
Lancet. 2008 Sep 20;372(9643):1021-2. doi: 10.1016/S0140-6736(08)61423-3.
4
The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis.使用吸入性糖皮质激素的哮喘患者中长效β受体激动剂的安全性：系统评价和荟萃分析。
Am J Respir Crit Care Med. 2008 Nov 15;178(10):1009-16. doi: 10.1164/rccm.200804-494OC. Epub 2008 Sep 5.
5
Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials.长效β受体激动剂：哮喘临床试验中福莫特罗安全性数据综述
Eur Respir J. 2009 Jan;33(1):21-32. doi: 10.1183/09031936.00145006. Epub 2008 Sep 3.
6
Inhaled Glucocorticosteroid and Long-Acting beta(2)-Adrenoceptor Agonist Single-Inhaler Combination for Both Maintenance and Rescue Therapy : A Paradigm Shift in Asthma Management.吸入性糖皮质激素与长效β₂肾上腺素能受体激动剂单吸入器联合用于维持和急救治疗：哮喘管理的范式转变
Treat Respir Med. 2006;5(6):385-91. doi: 10.2165/00151829-200605060-00003.
7
Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids.长效吸入型β受体激动剂支气管扩张剂与吸入性糖皮质激素联合使用时的安全性和有效性。
Ann Intern Med. 2006 Nov 7;145(9):692-4. doi: 10.7326/0003-4819-145-9-200611070-00012.
8
Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths.荟萃分析：长效β受体激动剂对严重哮喘急性加重和哮喘相关死亡的影响。
Ann Intern Med. 2006 Jun 20;144(12):904-12. doi: 10.7326/0003-4819-144-12-200606200-00126. Epub 2006 Jun 5.
9
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.沙美特罗多中心哮喘研究试验：哮喘常规药物治疗与常规药物治疗加沙美特罗的比较。
Chest. 2006 Jan;129(1):15-26. doi: 10.1378/chest.129.1.15.
10
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.能否实现指南定义的哮喘控制？“获得最佳哮喘控制”研究。
Am J Respir Crit Care Med. 2004 Oct 15;170(8):836-44. doi: 10.1164/rccm.200401-033OC. Epub 2004 Jul 15.
Zotero 插件